Source:http://linkedlifedata.com/resource/pubmed/id/20435017
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-5-31
|
pubmed:abstractText |
The Janus kinase family consists of four members: JAK-1, -2, -3 and TYK-2. While JAK-2 and JAK-3 have been well characterized biochemically, there is little data on TYK-2. Recent work suggests that TYK-2 may play a critical role in the development of a number of inflammatory processes. We have carried out a series of biochemical studies to better understand TYK-2 enzymology and its inhibition profile, in particular how the TYK-2 phosphorylated forms differ from each other and from the other JAK family members. We have expressed and purified milligram quantities of the TYK-2 kinase domain (KD) to high purity and developed a method to separate the non-, mono- (pY(1054)) and di-phosphorylated forms of the enzyme. Kinetic studies (k(cat(app))/K(m(app))) indicated that phosphorylation of the TYK-2-KD (pY(1054)) increased the catalytic efficiency 4.4-fold compared to its non-phosphorylated form, while further phosphorylation to generate the di-phosphorylated enzyme imparted no further increase in activity. These results are in contrast to those obtained with the JAK-2-KD and JAK-3-KD, where little or no increase in activity occurred upon mono-phosphorylation, while di-phosphorylation resulted in a 5.1-fold increase in activity for the JAK-2-KD. Moreover, ATP-competitive inhibitors demonstrated 10-30-fold shifts in potency (K(i(app))) as a result of the TYK-2-KD phosphorylation state, while the shifts for JAK-3-KD were only 2-3-fold and showed little or no change for JAK-2-KD. Thus, the phosphorlyation state imparted differential effects on both activity and inhibition within the JAK family of kinases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1090-2104
|
pubmed:author |
pubmed-author:BrownStacyS,
pubmed-author:ChrencikJill EJE,
pubmed-author:DayJacqueline EJE,
pubmed-author:EmmonsThomas LTL,
pubmed-author:FischerH DavidHD,
pubmed-author:GormleyJennifer AJA,
pubmed-author:HallTroiiT,
pubmed-author:HirschJeffrey LJL,
pubmed-author:KorniskiBrianB,
pubmed-author:LeoneJoseph WJW,
pubmed-author:SommersCynthia DCD,
pubmed-author:TomasselliAlfredo GAG,
pubmed-author:WeinbergRobin ARA,
pubmed-author:WittwerArthur JAJ,
pubmed-author:WrightstoneAnn DAD
|
pubmed:copyrightInfo |
Copyright (c) 2010 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
28
|
pubmed:volume |
396
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
543-8
|
pubmed:meshHeading |
pubmed-meshheading:20435017-Animals,
pubmed-meshheading:20435017-Catalysis,
pubmed-meshheading:20435017-Humans,
pubmed-meshheading:20435017-Janus Kinase 2,
pubmed-meshheading:20435017-Janus Kinase 3,
pubmed-meshheading:20435017-Mice,
pubmed-meshheading:20435017-Phosphorylation,
pubmed-meshheading:20435017-Protein Structure, Tertiary,
pubmed-meshheading:20435017-TYK2 Kinase
|
pubmed:year |
2010
|
pubmed:articleTitle |
Expression, purification, and characterization of TYK-2 kinase domain, a member of the Janus kinase family.
|
pubmed:affiliation |
Pfizer Inc, Global Research and Development, St Louis Laboratories, 700 Chesterfield Parkway West, St Louis, MO 63017-1732, USA.
|
pubmed:publicationType |
Journal Article
|